A 4-week randomized double-blind placebo controlled parallel group phase II study to assess the efficacy and safety of gefitinib tablets 250 mg once daily (OD) in adult patients with moderate chronic obstructive pulmonary disease (COPD).
Study identifier:D1450C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 4-week randomized double-blind placebo controlled parallel group phase II study to assess the efficacy and safety of gefitinib tablets 250 mg once daily (OD) in adult patients with moderate chronic obstructive pulmonary disease (COPD).
Medical condition
Chronic Obstructive Pulmonary Disease
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jun 2006
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
